Although this is only a single case-report we believe it to be valuable because the cardiac function of our patient recovered, despite the severity of heart failure without a previous exposure to anthracyclines, following adequate cardiac management, allowing her to benefit from prolonged trastuzumab treatment followed by additional anti-HER2 agent lapatinib treatment. Here, ERBB2 is linked to heart failure.